Is TBGNF or VIG a better dividend investment in 2026?

TBGNF currently yields 1176.47% with a 5% 5-year dividend growth rate. VIG yields 1.64% with 9.2% growth. The better choice depends on your goal: TBGNF offers higher current income.

What is the dividend yield difference between TBGNF and VIG?

TBGNF has a forward dividend yield of 1176.47% ($2.00/share annually). VIG yields 1.64% ($3.45/share annually). The yield gap is 1174.83 percentage points.

Home › Compare › TBGNF vs VIG

TBGNF vs VIG: Dividend Comparison 2026

TBGNF yields 1176.47% · VIG yields 1.64%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 TBGNF wins by $78814195.17M in total portfolio value

INVESTMENT

TIME HORIZON10 years

TBGNF

● Live price

1176.47%

Share price

$0.17

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$78814195.20M

Annual income

$67,523,701,253,088.38

Full TBGNF calculator →

VIG

Vanguard Dividend Appreciation ETF

● Live price

1.64%

Share price

$210.70

Annual div

$3.45

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$32.4K

Annual income

$179.15

Full VIG calculator →

Portfolio growth — TBGNF vs VIG

📍 TBGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	TBGNF	VIG
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, TBGNF + VIG cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

TBGNF pays

VIG pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TBGNF

Annual income on $10K today (after 15% tax)

$100,000.00/yr

After 10yr DRIP, annual income (after tax)

$57,395,146,065,125.13/yr

VIG

Annual income on $10K today (after 15% tax)

$139.33/yr

After 10yr DRIP, annual income (after tax)

$152.28/yr

At 15% tax rate, TBGNF beats the other by $57,395,146,064,972.84/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TBGNF + VIG for your $10,000?

TBGNF: 50%VIG: 50%

100% VIG50/50100% TBGNF

Portfolio after 10yr

$39407097.62M

Annual income

$33,761,850,626,633.77/yr

Blended yield

85.67%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TBGNF buys

VIG buys

No recent congressional trades found for TBGNF or VIG in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricTBGNFVIG

Forward yield	1176.47% ✓	1.64%
Annual dividend / share	$2.00	$3.45 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$78814195.20M ✓	$32.4K
Annual income after 10y	$67,523,701,253,088.38 ✓	$179.15
Total dividends collected	$77969765.27M ✓	$1.7K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: TBGNF vs VIG ($10,000, DRIP)

Year	TBGNF Portfolio	TBGNF Income/yr	VIG Portfolio	VIG Income/yr	Gap
1← crossover	$128,347	$117,647.06	$11,304	$163.92	+$117.0K → TBGNF
2	$1,548,514	$1,411,182.61	$12,759	$166.33	+$1.54M → TBGNF
3	$17,569,052	$15,912,142.01	$14,382	$168.52	+$17.55M → TBGNF
4	$187,523,354	$168,724,468.35	$16,192	$170.52	+$187.51M → TBGNF
5	$1,883,716,681	$1,683,066,692.55	$18,210	$172.34	+$1883.70M → TBGNF
6	$17,816,329,317	$15,800,752,468.33	$20,460	$173.98	+$17816.31M → TBGNF
7	$158,731,384,105	$139,667,911,735.60	$22,968	$175.48	+$158731.36M → TBGNF
8	$1,332,782,916,056	$1,162,940,335,063.89	$25,763	$176.83	+$1332782.89M → TBGNF
9	$10,551,863,503,163	$9,125,785,782,982.70	$28,878	$178.05	+$10551863.47M → TBGNF
10	$78,814,195,201,473	$67,523,701,253,088.38	$32,350	$179.15	+$78814195.17M → TBGNF

TBGNF vs VIG: Complete Analysis 2026

TBGNF — Stock

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Full TBGNF Calculator →

VIG — ETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →

📬

Get this TBGNF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TBGNF vs SCHD TBGNF vs JEPI TBGNF vs O TBGNF vs KO TBGNF vs MAIN TBGNF vs DGRO TBGNF vs NOBL TBGNF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.